title: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.
abstract: Pregabalin is a novel compound in development for the treatment of anxiety disorders. The safety and efficacy of pregabalin for the treatment of social anxiety disorder was evaluated in a double-blind, multicenter clinical trial in which 135 patients were randomized to 10 weeks of double-blind treatment with either pregabalin 150 mg/d. pregabalin 600 mg/d, or placebo. The primary efficacy parameter was change from baseline to end point in the Liebowitz Social Anxiety Scale (LSAS) total score. Safety was assessed through clinical and laboratory monitoring, and recording spontaneously reported adverse events. Ninety-four patients (70%) completed the 11-week double-blind treatment phase. LSAS total score was significantly decreased by pregabalin 600 mg/d treatment compared with placebo (P = 0.024, analysis of covariance). Significant differences (P < or = 0.05) between pregabalin 600 mg/d and placebo were seen on several secondary measures including the LSAS subscales of total fear, total avoidance, social fear, and social avoidance, and the Brief Social Phobia Scale fear subscale. Pregabalin 150 mg/d was not significantly better than placebo on any measures. Somnolence and dizziness were the most frequently occurring adverse events among patients receiving pregabalin 600 mg/d. In conclusion, pregabalin 600 mg/d was an effective and well-tolerated treatment of social anxiety disorder.
authors.affiliation: Pfizer Global Research and Development, New London, CT 06320, USA. atul_pande@groton.pfizer.com
authors.forename: Atul C
authors.initials: AC
authors.lastname: Pande
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Feltner
authors.forename: James W
authors.initials: JW
authors.lastname: Jefferson
authors.forename: Jonathan R T
authors.initials: JR
authors.lastname: Davidson
authors.forename: Mark
authors.initials: M
authors.lastname: Pollack
authors.forename: Murray B
authors.initials: MB
authors.lastname: Stein
authors.forename: R Bruce
authors.initials: RB
authors.lastname: Lydiard
authors.forename: Rïse
authors.initials: R
authors.lastname: Futterer
authors.forename: Paula
authors.initials: P
authors.lastname: Robinson
authors.forename: Mary
authors.initials: M
authors.lastname: Slomkowski
authors.forename: Eugene
authors.initials: E
authors.lastname: DuBoff
authors.forename: Mary
authors.initials: M
authors.lastname: Phelps
authors.forename: Carol A
authors.initials: CA
authors.lastname: Janney
authors.forename: John L
authors.initials: JL
authors.lastname: Werth
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069583:Pregabalin; D011569:Psychiatric Status Rating Scales; D012920:Social Behavior Disorders / Q000188:drug therapy* / Q000523:psychology; D015430:Weight Gain / Q000187:drug effects; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D014151:Anti-Anxiety Agents; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid